Bragar Eagel & Squire, P.C. Is Investigating Cassava, Cognyte, Singularity Future, and Lightwave Logic and Encourages Investors to Contact the Firm

NEW YORK, July 10, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ:SAVA ), Cognyte Software (NASDAQ:CGNT ), Singularity Future Technology, Inc. (NASDAQ:SGLY ), and Lightwave Logic, Inc. (NASDAQ:LWLG ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. Cassava Sciences, Inc. (NASDAQ:SAVA ) On April 18, 2022, The New York Times  published an article entitled "Scientists Question Data Behind an Experimental Alzheimer's Drug."  The article addressed Cassava's experimental Alzheimer's drug, simufilam, and reported that one of Cassava's advisers, Dr. H.Y. Wang, had five papers he authored retracted from the scientific journal PLoS One after an in-depth investigation revealed "serious concerns about the integrity and the reliability of the results." On this news, Cassava's stock price fell sharply during intraday trading on April 19, 2022. For more information on the Cassava investigation go to: https://bespc.com/cases/SAVA Cognyte Software (NASDAQ:CGNT ) On April 5, 2022, Cognyte reported its fourth quarter 2021 financial results, including revenue of $125 million, which was about $3.5 million below the midpoint of the Company's own guidance. Cognyte cited "lower conversions within ... Full story available on Benzinga.com